Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 277

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

METTL3 Inhibits Antitumor Immunity by Targeting m6A-BHLHE41-CXCL1/CXCR2 Axis to Promote Colorectal Cancer

Open access
Chen, Huarong, Pan, Yasi, Zhou, Qiming, Liang, Cong, Wong, Chi-Chun, Zhou, Yunfei, Huang, Dan, Liu, Weixin, Zhai, Jianning, Gou, Hongyan, Su, Hao, Zhang, Xiaoting, Xu, Hongzhi, Wang, Yifei, Kang, Wei, Kei Wu, William Ka, Yu, Jun·2022·Gastroenterology

Abstract

Background & Aims N 6 -Methyladenosine (m 6 A) is the most prevalent RNA modification and recognized as an important epitranscriptomic mechanism in colorectal cancer (CRC). We aimed to exploit whether and how tumor-intrinsic m 6 A modification driven by methyltransferase like 3 (METTL3) can dictate the immune landscape of CRC. Methods Mettl3 knockout mice, CD34 + humanized mice, and different syngeneic mice models were used. Immune cell composition and cytokine level were analyzed by flow cytometry and Cytokine 23-Plex immunoassay, respectively. M 6 A sequencing and RNA sequencing were performed to identify downstream targets and pathways of METTL3. Human CRC specimens (n = 176) were used to evaluate correlation between METTL3 expression and myeloid-derived suppressor cell (MDSC) infiltration. Results We demonstrated that silencing of METTL3 in CRC cells reduced MDSC accumulation to sustain activation and proliferation of CD4 + and CD8 + T cells, and eventually suppressed CRC in Apc Min/+ Mettl3 +/− mice, CD34 + humanized mice, and syngeneic mice models. Mechanistically, METTL3 activated the m 6 A-BHLHE41-CXCL1 axis by analysis of m 6 A sequencing, RNA sequencing, and cytokine arrays. METTL3 promoted BHLHE41 expression in an m 6 A-dependent manner, which subsequently induced CXCL1 transcription to enhance MDSC migration in vitro. However, the effect was negligible on BHLHE41 depletion, CXCL1 protein or CXCR2 inhibitor SB265610 administration, inferring that METTL3 promotes MDSC migration via BHLHE41-CXCL1/CXCR2. Consistently, depletion of MDSCs by anti-Gr1 antibody or SB265610 blocked the tumor-promoting effect of METTL3 in vivo. Importantly, targeting METTL3 by METTL3-single guide RNA or specific inhibitor potentiated the effect of anti–programmed cell death protein 1 (anti-PD1) treatment. Conclusions Our study identifies METTL3 as a potential therapeutic target for CRC immunotherapy whose inhibition reverses immune suppression through the m 6 A-BHLHE41-CXCL1 axis. METTL3 inhibition plus anti-PD1 treatment shows promising antitumor efficacy against CRC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2022.06.024

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 277

Metadata

Authors
Chen, H., Pan, Y., Zhou, Q., Liang, C., Wong, C.-C., Zhou, Y., Huang, D., Liu, W., Zhai, J., Gou, H., Su, H., Zhang, X., Xu, H., Wang, Y., Kang, W., Kei Wu, W. K., & Yu, J.
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2022-10
Volume
163
Issue
4
Pages
891-907
ISSN
0016-5085 (ISSN-L)
OpenAlex
W4282040212
Cited by
277
References
33
FWCI
16.02
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: METTL3 Inhibits Antitumor Immunity by Targeting m6A-BHLHE41-CXCL1/CXCR2 Axis to Promote Colorectal Cancer. https://app.cochat.ai/papers/10.1053/j.gastro.2022.06.024
The paper
Chen, H., Pan, Y., Zhou, Q., Liang, C., Wong, C.-C., Zhou, Y., Huang, D., Liu, W., Zhai, J., Gou, H., Su, H., Zhang, X., Xu, H., Wang, Y., Kang, W., Kei Wu, W. K., & Yu, J. (2022). METTL3 Inhibits Antitumor Immunity by Targeting m6A-BHLHE41-CXCL1/CXCR2 Axis to Promote Colorectal Cancer. Gastroenterology. https://doi.org/10.1053/j.gastro.2022.06.024

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.